Richard D. Wasnich

TL;DR: In this paper, the authors found that risedronate increases bone mineral density in elderly women, but whether it prevents hip fracture is not known, and the women were randomly assigned to receive treatment with either oral risingronate (2.5 or 5.0 mg) or placebo for three years.

TL;DR: Combining information about bone mass and prevalent fracture appears to be better for predicting new fractures than either variable alone and Physicians can use these risk factors to identify patients at greatest risk for new fractures.

TL;DR: A prospective, two-year, double-blind, placebo-controlled, multicenter study in 429 women who had one to four vertebral compression fractures plus radiographic evidence of osteopenia to determine the effects of etidronate in the treatment of postmenopausal osteoporosis.

TL;DR: A meta-analysis of all randomized, placebo-controlled trials of antiresorptive agents conducted in postmenopausal women with osteoporosis demonstrated that larger increases in BMD at both the spine and hip and larger reductions in both formation and resorption BCM are associated with greater reductions in the risk of nonvertebral fractures.

TL;DR: Data from clinical trials of antiresorptive agents was compiled and the relative risk of vertebral fractures against the average change in BMD for each trial was plotted, consistent with the short-term predictions of the conceptual model and with reports from randomized trials.